Compare Abbott India with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs DIVIS LABORATORIES - Comparison Results

ABBOTT INDIA     Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA DIVIS LABORATORIES ABBOTT INDIA/
DIVIS LABORATORIES
 
P/E (TTM) x 46.9 58.6 79.9% View Chart
P/BV x 15.3 13.5 113.3% View Chart
Dividend Yield % 0.4 0.5 99.3%  

Financials

 ABBOTT INDIA   DIVIS LABORATORIES
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-19
DIVIS LABORATORIES
Mar-19
ABBOTT INDIA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs8,8341,639 538.9%   
Low Rs5,4581,115 489.5%   
Sales per share (Unadj.) Rs1,731.1186.3 929.1%  
Earnings per share (Unadj.) Rs211.951.0 415.9%  
Cash flow per share (Unadj.) Rs219.957.3 383.6%  
Dividends per share (Unadj.) Rs65.0016.00 406.3%  
Dividend yield (eoy) %0.91.2 78.3%  
Book value per share (Unadj.) Rs945.2261.8 361.1%  
Shares outstanding (eoy) m21.25265.47 8.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.17.4 55.8%   
Avg P/E ratio x33.727.0 124.8%  
P/CF ratio (eoy) x32.524.0 135.3%  
Price / Book Value ratio x7.65.3 143.7%  
Dividend payout %30.731.4 97.7%   
Avg Mkt Cap Rs m151,848365,592 41.5%   
No. of employees `0003.511.8 29.4%   
Total wages/salary Rs m4,3565,423 80.3%   
Avg. sales/employee Rs Th10,555.54,175.1 252.8%   
Avg. wages/employee Rs Th1,249.9457.7 273.1%   
Avg. net profit/employee Rs Th1,292.21,141.8 113.2%   
INCOME DATA
Net Sales Rs m36,78649,463 74.4%  
Other income Rs m1,1331,556 72.8%   
Total revenues Rs m37,91951,019 74.3%   
Gross profit Rs m6,04718,718 32.3%  
Depreciation Rs m1691,689 10.0%   
Interest Rs m2335 64.3%   
Profit before tax Rs m6,98918,551 37.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,4855,023 49.5%   
Profit after tax Rs m4,50313,527 33.3%  
Gross profit margin %16.437.8 43.4%  
Effective tax rate %35.627.1 131.3%   
Net profit margin %12.227.3 44.8%  
BALANCE SHEET DATA
Current assets Rs m27,61046,501 59.4%   
Current liabilities Rs m8,5698,468 101.2%   
Net working cap to sales %51.876.9 67.3%  
Current ratio x3.25.5 58.7%  
Inventory Days Days60131 46.0%  
Debtors Days Days2786 31.9%  
Net fixed assets Rs m1,05725,797 4.1%   
Share capital Rs m213531 40.0%   
"Free" reserves Rs m19,87368,962 28.8%   
Net worth Rs m20,08669,493 28.9%   
Long term debt Rs m00-   
Total assets Rs m29,40980,383 36.6%  
Interest coverage x311.6531.0 58.7%   
Debt to equity ratio x00-  
Sales to assets ratio x1.30.6 203.3%   
Return on assets %15.416.9 91.2%  
Return on equity %22.419.5 115.2%  
Return on capital %34.926.7 130.5%  
Exports to sales %00-   
Imports to sales %024.6 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA12,187 0.0%   
Fx inflow Rs m36941,238 0.9%   
Fx outflow Rs m4,91812,405 39.6%   
Net fx Rs m-4,54928,833 -15.8%   
CASH FLOW
From Operations Rs m4,9919,543 52.3%  
From Investments Rs m-2,570-6,854 37.5%  
From Financial Activity Rs m-1,428-2,459 58.1%  
Net Cashflow Rs m993230 432.6%  

Share Holding

Indian Promoters % 0.0 52.0 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 11.8 66.9%  
FIIs % 0.1 19.0 0.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 17.2 99.4%  
Shareholders   18,270 31,796 57.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   SUN PHARMA  ORCHID PHARMA  SANOFI INDIA  FULFORD INDIA  PROCTER & GAMBLE HEALTH  

Compare ABBOTT INDIA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Plunges 746 Points; Banking & Metal Stocks Bleed(Closing)

Indian share markets witnessed huge selling pressure today and extended losses as the session progressed, dragged down by heavy selling in metal and banking stocks.

Related Views on News

ABBOTT INDIA Announces Quarterly Results (1QFY21); Net Profit Up 54.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 54.2% YoY). Sales on the other hand came in at Rs 11 bn (up 6.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY21); Net Profit Up 84.1% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

ABBOTT INDIA Announces Quarterly Results (4QFY20); Net Profit Down 2.0% (Quarterly Result Update)

Jun 9, 2020 | Updated on Jun 9, 2020

For the quarter ended March 2020, ABBOTT INDIA has posted a net profit of Rs 1 bn (down 2.0% YoY). Sales on the other hand came in at Rs 10 bn (up 6.1% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY20); Net Profit Up 35.4% (Quarterly Result Update)

Jun 8, 2020 | Updated on Jun 8, 2020

For the quarter ended March 2020, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 35.4% YoY). Sales on the other hand came in at Rs 14 bn (up 9.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

ABBOTT INDIA Announces Quarterly Results (3QFY20); Net Profit Up 59.5% (Quarterly Result Update)

Feb 11, 2020 | Updated on Feb 11, 2020

For the quarter ended December 2019, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 59.5% YoY). Sales on the other hand came in at Rs 11 bn (up 13.8% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

More Views on News

Most Popular

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

A Rare Chance to Invest in Potential Multibaggers in 2021(Profit Hunter)

Jan 11, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Jan 22, 2021 03:36 PM

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA - NOVARTIS COMPARISON

COMPARE ABBOTT INDIA WITH

MARKET STATS